Published in Pharma Law Weekly, January 10th, 2006
The results were released by Eli Lilly and Company at a meeting of a major scientific society.
In this 8-week study, Cymbalta, a serotonin and norepinephrine reuptake inhibitor, was effective in reducing depression symptoms (defined as onset of efficacy) by 2 weeks for 42% of patients. Within the same time period, 35% of patients taking Lexapro, a selective serotonin reuptake inhibitor, and 22% of patients who received a sugar pill...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.